Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has decreased by 1.20%
Final update on transfer Over the Counter Business Undertaking of the Company as a going concern on a slump sale basis to Mankind Consumer Products Private Limited, a wholly owned subsidiary | Download
Final update on transfer Over the Counter Business Undertaking of the Company as a going concern on a slump sale basis to Mankind Consumer Products Private Limited, a wholly owned subsidiary | Download
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 1.63%